The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immune checkpoint inhibitors (ICIs) and BRAF/MEK-targeted therapies have changed the treatment landscape dramatically. Combination therapies are playing an increasingly greater role in the unresectable recurrent or metastatic setting, including regimens such as Novartis’s Tafinlar plus Mekinist (2014), Roche/Genentech’s Zelboraf plus Cotellic (2015), and Bristol-Myers Squibb’s Opdivo plus Yervoy (2015). Consequently, optimizing sequencing decisions is a key focus for prescribing oncologists, irrespective of patients’ BRAF mutation status.
Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast
The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol-Myers Squibb), as well as
Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into...
Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis (US)
Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination r...
Malignant Melanoma | Disease Landscape and Forecast | G7 | 2019
Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both...